title: [L-MTP-PE--a potential antineoplastic agent].
abstract: Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic lipophilic analogue of muramyl dipeptide, stimulates monocytes/macrophages to kill a variety of tumor cells in vitro and in vivo. Encapsulation of MTP-PE into multilamellar liposomes (L-MTP-PE) was specifically designed for in vivo targeting to macrophages by i.v. infusion and is the only form of the drug currently available for clinical trials (CGP 19835A Lipid). L-MTP-PE is presently undergoing clinical trials in patients with recurrent osteosarcoma and melanoma. L-MTP-PE combined with other anticancer agents may thus improve long-term cure rates of patients with this diseases.
authors.affiliation: Katedra Chemii Organicznej, Politechniki Gdańskiej w Gdańsku.
authors.forename: K
authors.initials: K
authors.lastname: Dzierzbicka
authors.forename: M
authors.initials: M
authors.lastname: Gozdowska
authors.forename: A M
authors.initials: AM
authors.lastname: Kołodziejczyk
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007262:Infusions, Intravenous; D008264:Macrophages / Q000187:drug effects; D008545:Melanoma / Q000188:drug therapy*; D012516:Osteosarcoma / Q000188:drug therapy*; D010714:Phosphatidylethanolamines / Q000494:pharmacology* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine
vernacular_title: L-MTP-PE--potencjalny lek przeciwnowotworowy.